Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity:clinical outcomes in advanced melanoma

Autor: Robert Mason, J.V. van Thienen, Henrik Schmidt, Oddbjørn Straume, Lars Bastholt, Christian U. Blank, M.H. Geukes Foppen, Simone M. Goldinger, Leena Tiainen, Marta Nyakas, Elisa A. Rozeman, Bart Neyns, Victoria Atkinson, Georgina V. Long, Inge Marie Svane, Y.J.L. Jansen, Teofila Seremet, A. Arance, Lise Hoejberg, Alexander M. Menzies, J.B.A.G. Haanen, Siru Mäkelä, Reinhard Dummer

Publikováno v: Jansen, Y J L, Rozeman, E A, Mason, R, Goldinger, S M, Geukes Foppen, M H, Højberg, L, Schmidt, H, van Thienen, J V, Haanen, J B A G, Tiainen, L, Svane, I M, Mäkelä, S, Seremet, T, Arance, A, Dummer, R, Bastholt, L, Nyakas, M, Straume, O, Menzies, A M, Long, G V, Atkinson, V, Blank, C U & Neyns, B 2019, ' Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity : clinical outcomes in advanced melanoma ', Annals of Oncology, vol. 30, no. 7, pp. 1154-1161 . https://doi.org/10.1093/annonc/mdz110
Jansen, Y J L, Rozeman, E A, Mason, R, Goldinger, S M, Geukes Foppen, M H, Hoejberg, L, Schmidt, H, Van Thienen, J V, Haanen, J B A G, Tiainen, L, Svane, I M, Mäkelä, S, Seremet, T, Arance, A, Dummer, R, Bastholt, L, Nyakas, M, Straume, O, Menzies, A M, Long, G V, Atkinson, V, Blank, C U & Neyns, B 2019, ' Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity : clinical outcomes in advanced melanoma ', Annals of Oncology, vol. 30, no. 7, mdz110, pp. 1154-1161 . https://doi.org/10.1093/annonc/mdz110
Jansen, Y J L, Rozeman, E A, Mason, R, Goldinger, S M, Geukes Foppen, M H, Hoejberg, L, Schmidt, H, Van Thienen, J V, Haanen, J B A G, Tiainen, L, Svane, I M, Mäkelä, S, Seremet, T, Arance, A, Dummer, R, Bastholt, L, Nyakas, M, Straume, O, Menzies, A M, Long, G V, Atkinson, V, Blank, C U & Neyns, B 2019, ' Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity : clinical outcomes in advanced melanoma ', Annals of Oncology, vol. 30, no. 7, pp. 1154-1161 . https://doi.org/10.1093/annonc/mdz110

BACKGROUND: Programmed cell death protein 1 (PD-1) blocking monoclonal antibodies improve the overall survival of patients with advanced melanoma but the optimal duration of treatment has not been established.PATIENTS AND METHODS: This academic real-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acb2426cfdad8323d67c5bd20e80a59e
https://curis.ku.dk/portal/da/publications/discontinuation-of-antipd1-antibody-therapy-in-the-absence-of-disease-progression-or-treatment-limiting-toxicity(00dd1bed-a3b3-45b5-b8d4-f911468c6499).html

Results of a phase I trial with MART-1 T cell receptor modified T cells in patients with metastatic melanoma

Autor: Christian U. Blank, Sofie Wilgenhof, J.B.A.G. Haanen, Loes M. Pronk, Maartje W. Rohaan, J.H. van den Berg, B.A. van de Wiel, T.N. Schumacher, A. Sari, Ferry Lalezari, H. van Tinteren, Raquel Gomez-Eerland, H. Mallo, M. van Zon, Bastiaan Nuijen, J.V. van Thienen, M.H. Geukes Foppen, J. H. Beijnen, R. De Boer, Noor A. M. Bakker

Publikováno v: Annals of Oncology. 30:v481-v482

Background Adoptive cell therapy (ACT) with T cell receptor (TCR) gene modified peripheral blood T cells creates large pools of tumor reactive T cells. Based on preclinical validation we have selected a high affinity MART-1-specific TCR for TCR gene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9b3374e4370635ab1a9b126103cb46e1
https://doi.org/10.1093/annonc/mdz253.010

Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression

Autor: H. van Tinteren, J.B.A.G. Haanen, Christian U. Blank, A. Scholtens, J.V. van Thienen, M.H. Geukes Foppen

Publikováno v: European Journal of Cancer. 51:642-652

Background Selective BRAF inhibition (BRAFi) by vemurafenib or dabrafenib has become approved standard treatment in BRAF V600 mutated advanced stage melanoma. While the response rate is high, the response duration is limited with a progression-free s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09fe2cb4cae628f7cac178c9d319b2d9
https://doi.org/10.1016/j.ejca.2015.01.009

Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma

Autor: Christian U. Blank, Marco Donia, Bastiaan Nuijen, J.H. van den Berg, J.V. van Thienen, R. De Boer, A.C.J. van Akkooi, Maartje W. Rohaan, M.H. Geukes Foppen, T.H. Borch, Loes M. Pronk, Sofie Wilgenhof, J.B.A.G. Haanen, Özcan Met, M. van Zon, E.A.M. Bakker, Inge Marie Svane

Publikováno v: Annals of oncology, 29. Oxford University Press

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abb0fcd209bf848e28b9252a150a27c6
https://doi.org/10.1093/annonc/mdy289.059